search
Back to results

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

Primary Purpose

Atopic Dermatitis, Atopic Dermatitis Eczema

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Dupilumab
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atopic Dermatitis focused on measuring atopic dermatitis, eczema, dupilumab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ability to provide written informed consent and comply with the protocol
  • At least 18 years of age
  • Diagnosis of atopic dermatitis at least 6 months prior to enrollment, having stable (unchanged) disease for at least 2 months
  • Non-immune-compromised status
  • Subjects have moderate-to-severe atopic dermatitis, classified as Eczema Area and Severity Index (EASI) score greater than or equal to 6
  • Subject is considered a candidate for phototherapy or systemic therapy
  • Subjects of child-bearing potential must have a negative urine pregnancy test within 7 days prior to first dose of dupilumab
  • Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study
  • Subject meets concomitant medication requirements (see below)

Exclusion Criteria:

  • Younger than 18 years of age
  • Has mild atopic dermatitis, classified as EASI score less than 6
  • History of known or suspected intolerance to any of the ingredients of the investigational study product
  • Evidence of skin conditions other than atopic dermatitis that would interfere with study-related evaluations of atopic dermatitis.
  • History of immune-compromised status [e.g. human immunodeficiency virus (HIV) positive status or other immune suppressing drug] or a congenital or acquired immunodeficiency or subject testing positive for HIV during screening procedures
  • Has a poorly controlled medical condition including, but not limited to, unstable cardiovascular disease, poorly controlled diabetes, recent stroke, history of recurrent infections, or any other condition for which, in the opinion of the investigator, participation in the study would place the subject at risk
  • Has a history of or ongoing drug or alcohol abuse
  • Is not willing to comply with concomitant medication requirements
  • Is known, or suspected of being unable to comply with the study protocol
  • Subjects who are well controlled on current treatment for atopic dermatitis and participation in the study may worsen disease control significantly

Sites / Locations

  • UCSF Psoriasis and Skin Treatment Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Dupilumab treatment

Arm Description

30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).

Outcomes

Primary Outcome Measures

Psychological General Well-Being scale (PGWB)
The primary endpoint is the improvement in quality of life measured by change in Psychological General Well-Being scale (PGWB) at Week 16 from baseline. It is a self-reported, 22 item questionnaire, scored 0-5 and summed. PGWB will be administered at every study visit.

Secondary Outcome Measures

Work Productivity and Activity Impairment scale (WPAI:SHP)
Improvement in work productivity measured by change in Work Productivity and Activity Impairment scale (WPAI) at Week 16 from baseline. It measures the effect of health and symptom severity on work productivity and nonwork activities by assessing absenteeism, presenteeism, and impairment of daily activities. There are 6 questions, each with unique answers. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity. Scoring equations: Percent work time missed due to problem: Q2/(Q2+Q4) Percent impairment while working due to problem: Q5/10 Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))x(Q5/10)] Percent activity impairment due to problem: Q6/10
Dermatology Life Quality Index (DLQI)
Improvement in quality of life measured by change in Dermatology Life Quality Index (DLQI) at Week 16 from baseline. It is a 10 item questionnaire with a final score calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Treatment Satisfaction Questionnaire for Medication (TSQM)
Assessment of patient satisfaction with treatment measured by change in Treatment Satisfaction Questionnaire for Medication (TSQM) at Week 16 from baseline. TSQM is a 14-item questionnaire with 4 domains: effectiveness, convenience, global satisfaction, and side effects. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100, with higher scores indicating greater satisfaction.
Itch Numerical Rating Scale
Improvement in itch scores using numerical rating scales at Week 16 from baseline. This is a 0-10 scale with 0 equaling No itch, and 10 being Worst imaginable itch. Patients will circle number that describes the itch experienced from atopic dermatitis.
Pain Numerical Rating Scale
Improvement in pain scores using numerical rating scales at Week 16 from baseline. This is a 0-10 numerical scale with 10 as the worst imaginable itch. Patients circle the number that best describes the pain experienced from atopic dermatitis.
PSQI
Improvement in sleep quality measured by the Pittsburgh Sleep Quality Assessment (PSQI) at Week 16 from baseline. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

Full Information

First Posted
September 10, 2018
Last Updated
January 5, 2023
Sponsor
University of California, San Francisco
Collaborators
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT03667014
Brief Title
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
Official Title
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
December 15, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
Regeneron Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
Detailed Description
This is a single center, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis (AD). Thirty patients with moderate to severe AD will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 48). Improvement in patient quality of life after 52 weeks of treatment with dupilumab will be evaluated using validated dermatologic and non-dermatologic psychometric instruments. The primary endpoint is the improvement in quality of life measured by change in Psychological General Well-Being scale (PGWB) at Week 16 from baseline. Additionally, patients will be given a video recording device to document their experience with the study drug at home. Video footage of patient experiences will be compiled at the end of the study. The compiled video footage will subsequently be watched and analyzed to further understand the experiences of atopic dermatitis patients, and how undergoing dupilumab treatment alters these patients' experiences and attitudes with their skin disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis, Atopic Dermatitis Eczema
Keywords
atopic dermatitis, eczema, dupilumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dupilumab treatment
Arm Type
Experimental
Arm Description
30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
Intervention Type
Drug
Intervention Name(s)
Dupilumab
Other Intervention Name(s)
Dupixent
Intervention Description
Dupilumab treatment
Primary Outcome Measure Information:
Title
Psychological General Well-Being scale (PGWB)
Description
The primary endpoint is the improvement in quality of life measured by change in Psychological General Well-Being scale (PGWB) at Week 16 from baseline. It is a self-reported, 22 item questionnaire, scored 0-5 and summed. PGWB will be administered at every study visit.
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Work Productivity and Activity Impairment scale (WPAI:SHP)
Description
Improvement in work productivity measured by change in Work Productivity and Activity Impairment scale (WPAI) at Week 16 from baseline. It measures the effect of health and symptom severity on work productivity and nonwork activities by assessing absenteeism, presenteeism, and impairment of daily activities. There are 6 questions, each with unique answers. WPAI outcomes are expressed as impairment percentages (0-100), with higher numbers indicating greater impairment and less productivity. Scoring equations: Percent work time missed due to problem: Q2/(Q2+Q4) Percent impairment while working due to problem: Q5/10 Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))x(Q5/10)] Percent activity impairment due to problem: Q6/10
Time Frame
16 weeks
Title
Dermatology Life Quality Index (DLQI)
Description
Improvement in quality of life measured by change in Dermatology Life Quality Index (DLQI) at Week 16 from baseline. It is a 10 item questionnaire with a final score calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time Frame
16 weeks
Title
Treatment Satisfaction Questionnaire for Medication (TSQM)
Description
Assessment of patient satisfaction with treatment measured by change in Treatment Satisfaction Questionnaire for Medication (TSQM) at Week 16 from baseline. TSQM is a 14-item questionnaire with 4 domains: effectiveness, convenience, global satisfaction, and side effects. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100, with higher scores indicating greater satisfaction.
Time Frame
16 weeks
Title
Itch Numerical Rating Scale
Description
Improvement in itch scores using numerical rating scales at Week 16 from baseline. This is a 0-10 scale with 0 equaling No itch, and 10 being Worst imaginable itch. Patients will circle number that describes the itch experienced from atopic dermatitis.
Time Frame
16 weeks
Title
Pain Numerical Rating Scale
Description
Improvement in pain scores using numerical rating scales at Week 16 from baseline. This is a 0-10 numerical scale with 10 as the worst imaginable itch. Patients circle the number that best describes the pain experienced from atopic dermatitis.
Time Frame
16 weeks
Title
PSQI
Description
Improvement in sleep quality measured by the Pittsburgh Sleep Quality Assessment (PSQI) at Week 16 from baseline. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ability to provide written informed consent and comply with the protocol At least 18 years of age Diagnosis of atopic dermatitis at least 6 months prior to enrollment, having stable (unchanged) disease for at least 2 months Non-immune-compromised status Subjects have moderate-to-severe atopic dermatitis, classified as Eczema Area and Severity Index (EASI) score greater than or equal to 6 Subject is considered a candidate for phototherapy or systemic therapy Subjects of child-bearing potential must have a negative urine pregnancy test within 7 days prior to first dose of dupilumab Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study Subject meets concomitant medication requirements (see below) Exclusion Criteria: Younger than 18 years of age Has mild atopic dermatitis, classified as EASI score less than 6 History of known or suspected intolerance to any of the ingredients of the investigational study product Evidence of skin conditions other than atopic dermatitis that would interfere with study-related evaluations of atopic dermatitis. History of immune-compromised status [e.g. human immunodeficiency virus (HIV) positive status or other immune suppressing drug] or a congenital or acquired immunodeficiency or subject testing positive for HIV during screening procedures Has a poorly controlled medical condition including, but not limited to, unstable cardiovascular disease, poorly controlled diabetes, recent stroke, history of recurrent infections, or any other condition for which, in the opinion of the investigator, participation in the study would place the subject at risk Has a history of or ongoing drug or alcohol abuse Is not willing to comply with concomitant medication requirements Is known, or suspected of being unable to comply with the study protocol Subjects who are well controlled on current treatment for atopic dermatitis and participation in the study may worsen disease control significantly
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tina Bhutani, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCSF Psoriasis and Skin Treatment Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94118
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28042711
Citation
Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017 Sep;28(6):488-491. doi: 10.1080/09546634.2016.1278198. Epub 2017 Jan 18.
Results Reference
background
PubMed Identifier
27305113
Citation
Drucker AM, Wang AR, Qureshi AA. Research Gaps in Quality of Life and Economic Burden of Atopic Dermatitis: The National Eczema Association Burden of Disease Audit. JAMA Dermatol. 2016 Aug 1;152(8):873-4. doi: 10.1001/jamadermatol.2016.1978. No abstract available.
Results Reference
background
PubMed Identifier
28300443
Citation
Nicholas MN, Gooderham MJ. Atopic Dermatitis, Depression, and Suicidality. J Cutan Med Surg. 2017 May/Jun;21(3):237-242. doi: 10.1177/1203475416685078. Epub 2017 Jan 9.
Results Reference
background
PubMed Identifier
28555328
Citation
Sidbury R, Khorsand K. Evolving Concepts in Atopic Dermatitis. Curr Allergy Asthma Rep. 2017 Jul;17(7):42. doi: 10.1007/s11882-017-0710-5.
Results Reference
background
PubMed Identifier
28503712
Citation
Simpson EL. Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials. Dermatol Ther (Heidelb). 2017 Jun;7(2):243-248. doi: 10.1007/s13555-017-0181-6. Epub 2017 May 13.
Results Reference
background

Learn more about this trial

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

We'll reach out to this number within 24 hrs